Prestige Consumer Healthcare (PBH) Financials

$79.75 -1.19 (-1.47%)

As of 03:09 PM Eastern

Annual Income Statements for Prestige Consumer Healthcare

This table shows Prestige Consumer Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	78	100	69	2,422	-36	142	165	205	-82	209
Consolidated Net Income / (Loss)	78	100	69	340	-36	142	165	205	-82	209
Net Income / (Loss) Continuing Operations	78	100	69	2,422	-36	142	165	205	-82	209
Total Pre-Tax Income	127	157	111	107	-38	191	204	262	-94	276
Total Operating Income	208	260	206	215	68	291	297	330	-22	342
Total Gross Profit	406	467	500	577	556	552	547	621	625	624
Total Revenue	715	806	882	3,124	976	963	943	1,087	1,128	1,125
Operating Revenue	710	803	882	1,041	976	963	943	1,087	1,128	1,125
Total Cost of Revenue	308	339	382	465	420	411	396	466	502	501
Operating Cost of Revenue	308	339	382	465	420	411	396	466	502	501
Total Operating Expenses	199	207	295	361	488	261	250	291	648	282
Selling, General & Admin Expense	81	72	89	85	90	89	83	107	107	106
Marketing Expense	100	111	128	147	143	147	141	157	145	153
Depreciation Expense	18	24	25	28	27	25	24	25	25	23
Impairment Charge	-	0.00	0.00	100	229	-	2.43	1.06	370	0.00
Total Other Income / (Expense), net	-80	-103	-95	-108	-106	-100	-93	-67	-72	-66
Interest Expense	81	103	95	109	105	98	95	66	69	67
Other Income / (Expense), net	1.13	-	-0.03	0.39	-0.48	-1.63	1.37	-1.05	-2.34	0.76
Income Tax Expense	49	57	41	-232	-2.26	49	39	57	-12	67
Basic Earnings per Share	$1.50	$1.89	$1.31	$6.40	($0.69)	$2.81	$3.28	$4.09	($1.65)	$4.21
Weighted Average Basic Shares Outstanding	52.17M	52.75M	52.98M	53.10M	52.07M	50.72M	50.21M	50.26M	49.89M	49.76M
Diluted Earnings per Share	$1.49	$1.88	$1.30	$6.34	($0.69)	$2.78	$3.25	$4.04	($1.65)	$4.17
Weighted Average Diluted Shares Outstanding	52.67M	53.14M	53.36M	53.53M	52.07M	51.14M	50.61M	50.84M	49.89M	50.18M
Weighted Average Basic & Diluted Shares Outstanding	52.20M	52.90M	53M	53.10M	51.90M	50.09M	49.91M	50.28M	49.69M	49.92M

This table shows Prestige Consumer Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Net Income / (Loss) Attributable to Common Shareholders	55	51	52	-241	53	54	53	49	49	54	61
Consolidated Net Income / (Loss)	55	51	52	-241	53	54	53	49	49	54	61
Net Income / (Loss) Continuing Operations	55	51	52	-241	53	54	53	49	49	54	61
Total Pre-Tax Income	71	67	68	-300	69	70	70	67	58	72	80
Total Operating Income	87	84	87	-281	85	88	87	82	72	84	92
Total Gross Profit	160	161	150	154	155	160	158	152	146	157	161
Total Revenue	277	289	276	286	279	286	283	277	267	284	290
Operating Revenue	277	289	276	286	279	286	283	277	267	284	290
Total Cost of Revenue	117	128	125	132	125	126	125	125	121	126	129
Operating Cost of Revenue	117	128	125	132	125	126	125	125	121	126	129
Total Operating Expenses	73	77	63	435	69	72	71	70	74	73	69
Selling, General & Admin Expense	27	26	27	28	28	26	26	26	29	26	26
Marketing Expense	40	44	30	31	36	40	39	38	39	41	38
Depreciation Expense	6.44	6.37	6.26	6.01	5.56	5.67	5.64	5.68	5.70	5.57	4.96
Total Other Income / (Expense), net	-16	-18	-19	-19	-16	-18	-17	-15	-14	-13	-12
Interest Expense	15	17	18	19	18	18	17	15	13	12	11
Other Income / (Expense), net	-0.83	-0.81	-1.15	0.45	1.24	-0.23	-0.68	0.43	-0.50	-0.40	-0.35
Income Tax Expense	16	16	16	-59	15	17	17	18	9.35	17	19
Basic Earnings per Share	$1.10	$1.02	$1.05	($4.82)	$1.07	$1.08	$1.07	$0.99	$0.98	$1.10	$1.23
Weighted Average Basic Shares Outstanding	50.26M	49.80M	49.69M	49.89M	49.77M	49.69M	49.74M	49.76M	49.89M	49.65M	49.60M
Diluted Earnings per Share	$1.09	$1.02	$1.04	($4.80)	$1.06	$1.07	$1.06	$0.98	$0.98	$1.09	$1.22
Weighted Average Diluted Shares Outstanding	50.73M	50.27M	50.19M	49.89M	50.20M	50.08M	50.13M	50.18M	50.27M	50.00M	49.99M
Weighted Average Basic & Diluted Shares Outstanding	49.76M	49.53M	49.69M	49.69M	49.54M	49.62M	49.65M	49.92M	49.56M	49.41M	49.54M

This table details how cash moves in and out of Prestige Consumer Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-7.01	5.91	15	-9.31	-5.02	67	-62	-5.12	31	-12
Net Cash From Operating Activities	156	176	149	210	189	217	236	260	230	249
Net Cash From Continuing Operating Activities	156	176	149	210	189	217	236	260	230	249
Net Income / (Loss) Continuing Operations	78	100	69	340	-36	142	165	205	-82	209
Consolidated Net Income / (Loss)	78	100	69	340	-36	142	165	205	-82	209
Depreciation Expense	18	24	26	33	32	29	30	32	33	31
Amortization Expense	8.82	8.99	8.63	6.74	5.92	3.81	4.98	4.23	4.36	5.24
Non-Cash Adjustments To Reconcile Net Income	6.89	20	64	115	236	11	16	13	383	13
Changes in Operating Assets and Liabilities, net	45	24	-19	-285	-49	31	20	5.48	-108	-9.63
Net Cash From Investing Activities	-805	-223	-695	-12	55	-17	-22	-257	-12	-20
Net Cash From Continuing Investing Activities	-805	-223	-695	-12	55	-17	-22	-257	-12	-20
Purchase of Property, Plant & Equipment	-6.10	-3.57	-2.98	-13	-10	-15	-22	-9.64	-7.78	-9.55
Other Investing Activities, net	-	-	-	0.97	0.00	0.75	0.00	-247	-	-11
Net Cash From Financing Activities	643	52	561	-209	-249	-131	-279	-7.57	-186	-241
Net Cash From Continuing Financing Activities	643	52	561	-209	-249	-131	-279	-7.57	-186	-241
Repayment of Debt	-205	-498	-979	-490	-245	-575	-883	-691	-155	-226
Repurchase of Common Equity	-	-	0.00	0.00	-50	-57	-12	0.00	-50	-25
Issuance of Debt	845	545	1,537	280	45	500	615	682	20	0.00
Other Financing Activities, net	3.18	4.47	2.60	0.55	0.65	-0.13	0.17	1.54	-0.85	9.75
Other Net Changes in Cash	-	-	-0.41	-	-	-	-	-0.96	-	0.18
Cash Interest Paid	70	79	85	99	98	92	80	61	54	63
Cash Income Taxes Paid	12	15	48	24	33	31	34	47	41	60

This table details how cash moves in and out of Prestige Consumer Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Net Change in Cash & Equivalents	8.68	6.57	44	-28	-3.91	5.49	3.55	-17	-12	17	-0.67
Net Cash From Operating Activities	58	58	55	59	48	62	71	67	55	70	65
Net Cash From Continuing Operating Activities	58	58	55	59	48	62	71	67	55	70	65
Net Income / (Loss) Continuing Operations	55	51	52	-241	53	54	53	49	49	54	61
Consolidated Net Income / (Loss)	55	51	52	-241	53	54	53	49	49	54	61
Depreciation Expense	8.38	8.25	8.13	7.86	7.54	7.64	7.65	7.84	8.12	7.93	6.87
Amortization Expense	0.83	0.97	0.82	1.75	0.98	1.32	1.42	1.51	0.45	0.43	0.43
Non-Cash Adjustments To Reconcile Net Income	4.21	3.44	2.48	373	3.65	3.70	7.66	3.55	3.25	2.05	2.81
Changes in Operating Assets and Liabilities, net	-10	-6.14	-8.44	-83	-17	-3.76	1.70	4.54	-6.12	5.02	-6.05
Net Cash From Investing Activities	-1.05	-2.38	-1.80	-6.36	2.32	-2.93	-4.50	-15	-2.13	-2.03	-9.82
Net Cash From Continuing Investing Activities	-1.05	-2.38	-1.80	-6.36	2.32	-2.93	-4.50	-15	-2.13	-2.03	-9.82
Purchase of Property, Plant & Equipment	-1.05	-2.38	-1.80	-2.56	-1.48	-2.93	-2.00	-3.14	-1.15	-2.03	-1.57
Net Cash From Financing Activities	-47	-48	-10	-80	-54	-54	-65	-68	-66	-51	-54
Net Cash From Continuing Financing Activities	-47	-48	-10	-80	-54	-54	-65	-68	-66	-51	-54
Repayment of Debt	-25	-35	-15	-80	-30	-55	-66	-75	-35	-40	-60
Repurchase of Common Equity	-38	-12	-	-	-25	-	-	-	-26	-12	-2.40
Other Financing Activities, net	-4.65	-0.68	4.98	-0.50	0.82	1.45	0.93	6.56	-4.55	0.62	8.54
Effect of Exchange Rate Changes	-	-	-	-	-0.14	-0.49	1.42	-	-	-	-2.08
Cash Interest Paid	3.56	15	18	18	18	16	16	14	14	12	12
Cash Income Taxes Paid	1.80	14	12	13	12	13	13	21	3.66	15	15

This table presents Prestige Consumer Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	2,642	2,949	3,911	3,761	3,441	3,514	3,429	3,671	3,354	3,318
Total Current Assets	202	249	334	303	301	366	270	293	392	375
Cash & Equivalents	21	27	42	33	28	95	32	27	58	46
Accounts Receivable	88	95	137	141	149	151	115	139	167	177
Inventories, net	74	91	116	119	120	116	115	120	162	139
Prepaid Expenses	10	25	40	12	4.74	4.35	7.90	6.41	4.12	13
Plant, Property, & Equipment, net	14	16	51	53	51	56	70	71	70	77
Total Noncurrent Assets	2,427	2,684	3,526	3,405	3,089	3,092	3,089	3,306	2,892	2,867
Noncurrent Note & Lease Receivables	-	-	-	-	0.00	5.84	8.99	6.86	4.20	1.54
Goodwill	291	360	615	620	579	575	578	579	528	528
Intangible Assets	2,135	2,323	2,904	2,781	2,507	2,479	2,476	2,697	2,342	2,321
Other Noncurrent Operating Assets	1.17	1.32	7.45	3.57	3.13	32	27	24	18	17
Total Liabilities & Shareholders' Equity	2,642	2,949	3,911	3,761	3,441	3,514	3,429	3,671	3,354	3,318
Total Liabilities	2,014	2,204	3,089	2,582	2,345	2,343	2,071	2,093	1,907	1,663
Total Current Liabilities	99	107	162	123	127	150	122	143	161	117
Accounts Payable	46	38	70	61	57	62	46	56	63	39
Accrued Expenses	41	60	84	52	61	71	61	74	73	56
Dividends Payable	12	8.66	8.13	9.71	9.76	9.91	6.31	4.44	16	16
Other Current Liabilities	-	-	-	-	0.00	6.83	8.45	9.11	9.76	6.15
Total Noncurrent Liabilities	1,915	2,098	2,927	2,459	2,218	2,193	1,949	1,950	1,746	1,546
Long-Term Debt	1,561	1,625	2,194	1,993	1,799	1,730	1,480	1,477	1,346	1,126
Capital Lease Obligations	-	-	-	-	0.00	30	27	21	12	7.70
Noncurrent Deferred & Payable Income Tax Liabilities	352	470	715	443	400	408	434	445	380	404
Other Noncurrent Operating Liabilities	2.46	2.84	18	23	20	25	8.61	7.48	8.17	9.19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	628	744	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655
Total Preferred & Common Equity	628	744	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	628	744	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655
Common Stock	427	446	459	469	480	489	500	516	536	568
Retained Earnings	227	327	397	736	702	844	1,009	1,214	1,132	1,341
Treasury Stock	-3.48	-5.16	-6.59	-7.67	-60	-118	-131	-134	-189	-220
Accumulated Other Comprehensive Income / (Loss)	-23	-24	-26	-19	-26	-44	-20	-19	-32	-34

This table presents Prestige Consumer Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Total Assets	3,659	3,682	3,679	3,750	3,346	3,333	3,340	3,308	3,317	3,329
Total Current Assets	275	325	337	409	392	388	394	369	381	377
Cash & Equivalents	21	36	42	86	55	60	64	34	52	51
Accounts Receivable	134	145	146	157	158	158	174	172	164	167
Inventories, net	106	134	141	159	170	161	149	152	156	152
Prepaid Expenses	14	9.53	7.71	6.89	9.38	8.39	7.25	11	9.40	7.50
Plant, Property, & Equipment, net	70	70	70	70	70	71	70	75	75	74
Total Noncurrent Assets	3,285	3,287	3,272	3,271	2,884	2,874	2,876	2,863	2,861	2,879
Noncurrent Note & Lease Receivables	-	6.19	5.53	4.86	3.54	2.87	2.21	0.88	0.21	4.94
Goodwill	579	577	576	577	527	527	528	528	529	527
Intangible Assets	2,704	2,683	2,671	2,670	2,336	2,328	2,329	2,318	2,317	2,311
Other Noncurrent Operating Assets	2.89	22	20	20	17	16	17	16	15	36
Total Liabilities & Shareholders' Equity	3,659	3,682	3,679	3,750	3,346	3,333	3,340	3,308	3,317	3,329
Total Liabilities	2,141	2,097	2,059	2,063	1,865	1,797	1,739	1,627	1,585	1,541
Total Current Liabilities	135	155	152	160	147	130	127	114	107	103
Accounts Payable	40	58	56	64	58	44	39	40	31	20
Accrued Expenses	71	73	71	71	65	60	65	55	57	61
Dividends Payable	15	15	16	15	15	16	15	15	16	15
Other Current Liabilities	-	9.32	9.44	9.67	9.46	9.61	7.84	4.45	2.65	6.92
Total Noncurrent Liabilities	453	1,942	1,906	1,903	1,718	1,667	1,612	1,513	1,478	1,439
Long-Term Debt	-	1,472	1,438	1,424	1,317	1,263	1,199	1,091	1,052	992
Capital Lease Obligations	-	3.80	3.09	14	9.16	0.22	6.33	7.20	0.13	28
Noncurrent Deferred & Payable Income Tax Liabilities	445	443	443	456	384	388	397	409	415	413
Other Noncurrent Operating Liabilities	8.43	23	22	8.87	8.18	16	8.92	5.14	12	5.03
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,518	1,585	1,620	1,687	1,480	1,536	1,601	1,681	1,732	1,788
Total Preferred & Common Equity	1,518	1,585	1,620	1,687	1,480	1,536	1,601	1,681	1,732	1,788
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,518	1,585	1,620	1,687	1,480	1,536	1,601	1,681	1,732	1,788
Common Stock	513	521	525	533	547	553	557	573	577	589
Retained Earnings	1,162	1,269	1,320	1,372	1,185	1,239	1,292	1,390	1,445	1,506
Treasury Stock	-134	-177	-189	-189	-220	-220	-220	-252	-263	-266
Accumulated Other Comprehensive Income / (Loss)	-23	-29	-36	-29	-32	-36	-29	-31	-27	-40

This table displays calculated financial ratios and metrics derived from Prestige Consumer Healthcare's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	19.63%	12.82%	9.40%	254.12%	-68.76%	-1.31%	-2.04%	15.21%	3.76%	-0.21%
EBITDA Growth	10.65%	24.54%	-18.07%	6.66%	-59.10%	207.78%	3.59%	9.37%	-96.65%	2,997.73%
EBIT Growth	10.64%	24.74%	-21.01%	4.99%	-68.95%	331.96%	3.19%	10.07%	-107.53%	1,486.55%
NOPAT Growth	-5.33%	29.83%	-22.19%	430.74%	-93.08%	358.64%	10.72%	7.59%	-106.08%	1,755.14%
Net Income Growth	7.77%	27.66%	-30.54%	389.33%	-110.54%	497.43%	15.74%	24.71%	-140.07%	354.34%
EPS Growth	7.19%	26.17%	-30.85%	387.69%	-110.88%	502.90%	16.91%	24.31%	-140.84%	352.73%
Operating Cash Flow Growth	40.04%	12.83%	-15.68%	41.32%	-9.91%	14.71%	8.51%	10.32%	-11.62%	8.36%
Free Cash Flow Firm Growth	-658.47%	98.94%	-8,194.20%	202.86%	-38.25%	-22.51%	-0.02%	-81.99%	516.93%	-4.14%
Invested Capital Growth	47.36%	7.87%	26.86%	5.57%	-8.64%	-1.07%	-0.26%	7.53%	-9.52%	-0.14%
Revenue Q/Q Growth	7.04%	2.26%	3.86%	204.47%	-72.56%	106.12%	-1.69%	2.76%	1.71%	-0.78%
EBITDA Q/Q Growth	10.04%	1.77%	-4.90%	-22.74%	-55.68%	205.15%	2.55%	1.73%	-96.69%	2,235.94%
EBIT Q/Q Growth	9.11%	1.57%	-5.61%	-25.99%	-66.06%	300.47%	2.66%	1.62%	-107.44%	1,820.83%
NOPAT Q/Q Growth	10.32%	0.02%	-4.57%	7.10%	-66.90%	327.49%	6.28%	2.25%	-105.92%	1,890.46%
Net Income Q/Q Growth	11.02%	-8.96%	-3.94%	-13.01%	-156.12%	686.53%	5.27%	8.78%	-139.13%	359.50%
EPS Q/Q Growth	12.03%	-9.62%	-3.70%	-13.03%	-156.10%	795.00%	5.86%	8.60%	-139.57%	359.01%
Operating Cash Flow Q/Q Growth	15.86%	-6.50%	-17.86%	28.75%	-1.86%	2.49%	1.27%	1.58%	-1.77%	3.29%
Free Cash Flow Firm Q/Q Growth	15.65%	-102.21%	-589.49%	218.73%	2.22%	-8.82%	4.24%	13.03%	7.14%	-6.41%
Invested Capital Q/Q Growth	-2.56%	10.46%	38.05%	-2.64%	-6.13%	0.08%	0.22%	0.23%	-9.57%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	56.84%	57.95%	56.72%	18.46%	56.94%	57.34%	58.03%	57.11%	55.45%	55.49%
EBITDA Margin	32.92%	36.34%	27.21%	8.20%	10.73%	33.47%	35.40%	33.60%	1.09%	33.69%
Operating Margin	29.04%	32.29%	23.31%	6.90%	6.92%	30.23%	31.53%	30.36%	-1.99%	30.43%
EBIT Margin	29.20%	32.29%	23.31%	6.91%	6.87%	30.07%	31.67%	30.26%	-2.19%	30.50%
Profit (Net Income) Margin	10.95%	12.39%	7.87%	10.87%	-3.67%	14.77%	17.46%	18.90%	-7.30%	18.60%
Tax Burden Percent	61.40%	63.56%	62.60%	317.10%	94.07%	74.43%	80.68%	78.25%	87.64%	75.84%
Interest Burden Percent	61.07%	60.38%	53.91%	49.61%	-56.78%	66.02%	68.32%	79.81%	379.44%	80.43%
Effective Tax Rate	38.60%	36.44%	37.40%	-217.10%	0.00%	25.57%	19.32%	21.75%	0.00%	24.16%
Return on Invested Capital (ROIC)	6.97%	7.30%	4.83%	22.29%	1.57%	7.57%	8.44%	8.77%	-0.54%	9.41%
ROIC Less NNEP Spread (ROIC-NNEP)	2.98%	3.15%	1.68%	5.64%	-2.86%	3.27%	3.67%	5.19%	-5.32%	5.24%
Return on Net Nonoperating Assets (RNNOA)	6.18%	7.26%	4.03%	11.65%	-4.72%	4.98%	4.58%	5.23%	-4.90%	4.09%
Return on Equity (ROE)	13.14%	14.56%	8.86%	33.94%	-3.15%	12.55%	13.02%	13.99%	-5.44%	13.50%
Cash Return on Invested Capital (CROIC)	-31.33%	-0.27%	-18.85%	16.87%	10.60%	8.65%	8.70%	1.51%	9.45%	9.55%
Operating Return on Assets (OROA)	9.41%	9.31%	5.99%	5.63%	1.86%	8.33%	8.61%	9.26%	-0.70%	10.29%
Return on Assets (ROA)	3.53%	3.57%	2.02%	8.85%	-0.99%	4.09%	4.74%	5.79%	-2.34%	6.28%
Return on Common Equity (ROCE)	13.14%	14.56%	8.86%	33.94%	-3.15%	12.55%	13.02%	13.99%	-5.44%	13.50%
Return on Equity Simple (ROE_SIMPLE)	12.47%	13.42%	8.44%	28.81%	-3.27%	12.15%	12.12%	13.02%	-5.69%	12.65%
Net Operating Profit after Tax (NOPAT)	127	165	129	683	47	217	240	258	-16	260
NOPAT Margin	17.83%	20.52%	14.60%	21.87%	4.84%	22.50%	25.44%	23.75%	-1.39%	23.08%
Net Nonoperating Expense Percent (NNEP)	3.99%	4.15%	3.15%	16.64%	4.43%	4.31%	4.77%	3.57%	4.78%	4.17%
Cost of Revenue to Revenue	43.16%	42.05%	43.28%	14.88%	43.06%	42.66%	41.97%	42.89%	44.55%	44.51%
SG&A Expenses to Revenue	11.37%	8.98%	10.10%	2.73%	9.20%	9.25%	8.81%	9.89%	9.52%	9.43%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	27.80%	25.66%	33.40%	11.56%	50.02%	27.11%	26.51%	26.75%	57.44%	25.06%
Earnings before Interest and Taxes (EBIT)	209	260	206	216	67	290	299	329	-25	343
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	235	293	240	256	105	322	334	365	12	379
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.53	3.74	3.53	1.50	1.41	1.57	1.62	1.68	2.15	2.18
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.10	3.45	3.29	0.57	1.59	1.91	2.33	2.45	2.76	3.20
Price to Earnings (P/E)	28.30	27.84	41.86	0.73	0.00	12.96	13.35	12.94	0.00	17.21
Dividend Yield	0.00%	0.00%	0.00%	0.00%	1.59%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.53%	3.59%	2.39%	137.11%	0.00%	7.72%	7.49%	7.73%	0.00%	5.81%
Enterprise Value to Invested Capital (EV/IC)	1.72	1.86	1.70	1.18	1.15	1.23	1.29	1.35	1.60	1.70
Enterprise Value to Revenue (EV/Rev)	5.25	5.43	5.73	1.19	3.40	3.64	3.89	3.80	3.91	4.17
Enterprise Value to EBITDA (EV/EBITDA)	15.96	14.95	21.07	14.56	31.70	10.89	11.00	11.30	360.42	12.37
Enterprise Value to EBIT (EV/EBIT)	17.99	16.83	24.59	17.26	49.54	12.12	12.29	12.55	0.00	13.66
Enterprise Value to NOPAT (EV/NOPAT)	29.46	26.47	39.28	5.45	70.27	16.19	15.30	15.99	0.00	18.06
Enterprise Value to Operating Cash Flow (EV/OCF)	24.03	24.84	34.01	17.74	17.54	16.16	15.58	15.88	19.20	18.84
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	7.21	10.40	14.18	14.84	92.66	16.05	17.80
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.49	2.18	2.67	1.69	1.64	1.50	1.11	0.95	0.94	0.68
Long-Term Debt to Equity	2.49	2.18	2.67	1.69	1.64	1.50	1.11	0.95	0.94	0.68
Financial Leverage	2.07	2.30	2.40	2.06	1.65	1.52	1.25	1.01	0.92	0.78
Leverage Ratio	3.73	4.08	4.38	3.83	3.17	3.07	2.75	2.42	2.32	2.15
Compound Leverage Factor	2.28	2.46	2.36	1.90	-1.80	2.03	1.88	1.93	8.81	1.73
Debt to Total Capital	71.33%	68.59%	72.73%	62.84%	62.14%	60.05%	52.58%	48.69%	48.40%	40.65%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	71.33%	68.59%	72.73%	62.84%	62.14%	60.05%	52.58%	48.69%	48.40%	40.65%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	28.67%	31.41%	27.27%	37.16%	37.86%	39.95%	47.42%	51.31%	51.60%	59.35%
Debt to EBITDA	6.64	5.55	9.14	7.78	17.17	5.46	4.51	4.10	110.91	2.99
Net Debt to EBITDA	6.55	5.45	8.96	7.66	16.91	5.17	4.41	4.03	106.13	2.87
Long-Term Debt to EBITDA	6.64	5.55	9.14	7.78	17.17	5.46	4.51	4.10	110.91	2.99
Debt to NOPAT	12.25	9.82	17.04	2.92	38.06	8.12	6.28	5.80	-86.51	4.36
Net Debt to NOPAT	12.08	9.66	16.72	2.87	37.48	7.68	6.14	5.69	-82.78	4.19
Long-Term Debt to NOPAT	12.25	9.82	17.04	2.92	38.06	8.12	6.28	5.80	-86.51	4.36
Altman Z-Score	1.36	1.54	1.16	1.76	1.09	1.43	1.66	1.87	1.85	2.64
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.04	2.33	2.06	2.46	2.37	2.44	2.21	2.04	2.44	3.20
Quick Ratio	1.10	1.15	1.10	1.41	1.39	1.64	1.20	1.16	1.40	1.91
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-573	-6.06	-503	517	319	247	247	45	275	263
Operating Cash Flow to CapEx	0.00%	5,468.67%	5,140.80%	1,676.59%	1,806.15%	1,491.24%	1,059.24%	2,695.73%	2,951.13%	2,606.56%
Free Cash Flow to Firm to Interest Expense	-7.05	-0.06	-5.29	4.74	3.04	2.52	2.61	0.67	3.97	3.92
Operating Cash Flow to Interest Expense	1.92	1.71	1.57	1.92	1.80	2.21	2.49	3.91	3.32	3.71
Operating Cash Flow Less CapEx to Interest Expense	1.97	1.68	1.54	1.81	1.70	2.06	2.25	3.77	3.21	3.56
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.32	0.29	0.26	0.81	0.27	0.28	0.27	0.31	0.32	0.34
Accounts Receivable Turnover	9.35	8.81	7.60	22.50	6.74	6.44	7.11	8.56	7.36	6.55
Inventory Turnover	4.42	4.10	3.69	3.97	3.52	3.48	3.43	3.96	3.56	3.33
Fixed Asset Turnover	61.23	55.06	26.67	60.56	18.81	17.97	14.97	15.38	15.92	15.32
Accounts Payable Turnover	6.53	8.03	7.04	7.06	7.13	6.91	7.31	9.16	8.48	9.85
Days Sales Outstanding (DSO)	39.05	41.45	48.00	16.22	54.18	56.72	51.30	42.65	49.58	55.75
Days Inventory Outstanding (DIO)	82.60	88.96	98.89	91.96	103.55	104.81	106.48	92.12	102.60	109.61
Days Payable Outstanding (DPO)	55.86	45.44	51.87	51.69	51.23	52.84	49.95	39.83	43.04	37.06
Cash Conversion Cycle (CCC)	65.79	84.97	95.02	56.50	106.50	108.69	107.83	94.94	109.13	128.30
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,180	2,351	2,983	3,149	2,877	2,846	2,838	3,052	2,762	2,758
Invested Capital Turnover	0.39	0.36	0.33	1.02	0.32	0.34	0.33	0.37	0.39	0.41
Increase / (Decrease) in Invested Capital	700	172	631	166	-272	-31	-7.44	214	-290	-3.73
Enterprise Value (EV)	3,754	4,380	5,057	3,727	3,320	3,509	3,672	4,128	4,411	4,690
Market Capitalization	2,214	2,782	2,905	1,766	1,549	1,844	2,198	2,658	3,112	3,603
Book Value per Share	$12.01	$14.11	$15.54	$22.22	$21.16	$23.30	$27.24	$31.43	$29.12	$33.34
Tangible Book Value per Share	($34.39)	($36.75)	($50.94)	($41.90)	($38.42)	($37.47)	($34.00)	($33.83)	($28.63)	($24.03)
Total Capital	2,189	2,370	3,016	3,172	2,894	2,931	2,864	3,075	2,804	2,789
Total Debt	1,561	1,625	2,194	1,993	1,799	1,760	1,506	1,497	1,357	1,134
Total Long-Term Debt	1,561	1,625	2,194	1,993	1,799	1,760	1,506	1,497	1,357	1,134
Net Debt	1,540	1,598	2,152	1,960	1,771	1,665	1,474	1,470	1,299	1,087
Capital Expenditures (CapEx)	-3.90	3.22	2.89	13	10	15	22	9.64	7.78	9.55
Debt-free, Cash-free Net Working Capital (DFCFNWC)	81	115	131	148	146	121	115	123	173	212
Debt-free Net Working Capital (DFNWC)	103	142	172	180	174	216	148	150	231	258
Net Working Capital (NWC)	103	142	172	180	174	216	148	150	231	258
Net Nonoperating Expense (NNE)	49	66	59	344	83	74	75	53	67	50
Net Nonoperating Obligations (NNO)	1,552	1,607	2,160	1,970	1,781	1,675	1,480	1,474	1,315	1,103
Total Depreciation and Amortization (D&A)	27	33	34	40	38	33	35	36	37	36
Debt-free, Cash-free Net Working Capital to Revenue	11.38%	14.28%	14.80%	4.73%	15.01%	12.57%	12.23%	11.29%	15.30%	18.80%
Debt-free Net Working Capital to Revenue	14.37%	17.65%	19.55%	5.77%	17.83%	22.41%	15.66%	13.79%	20.49%	22.93%
Net Working Capital to Revenue	14.37%	17.65%	19.55%	5.77%	17.83%	22.41%	15.66%	13.79%	20.49%	22.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.50	$1.89	$1.31	$6.40	($0.69)	$2.81	$3.28	$4.09	($1.65)	$4.21
Adjusted Weighted Average Basic Shares Outstanding	52.17M	52.75M	52.98M	53.10M	52.07M	50.72M	50.21M	50.26M	49.89M	49.76M
Adjusted Diluted Earnings per Share	$1.49	$1.88	$1.30	$6.34	($0.69)	$2.78	$3.25	$4.04	($1.65)	$4.17
Adjusted Weighted Average Diluted Shares Outstanding	52.67M	53.14M	53.36M	53.53M	52.07M	51.14M	50.61M	50.84M	49.89M	50.18M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($0.69)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	52.30M	52.76M	52.96M	53.07M	51.80M	50.09M	49.91M	50.28M	49.69M	49.92M
Normalized Net Operating Profit after Tax (NOPAT)	127	165	129	221	208	217	242	259	243	260
Normalized NOPAT Margin	17.83%	20.52%	14.60%	7.07%	21.30%	22.50%	25.64%	23.83%	21.59%	23.08%
Pre Tax Income Margin	17.84%	19.50%	12.57%	3.43%	-3.90%	19.85%	21.64%	24.15%	-8.33%	24.53%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.57	2.52	2.17	1.98	0.64	2.94	3.16	4.95	-0.36	5.11
NOPAT to Interest Expense	1.57	1.60	1.36	6.26	0.45	2.20	2.54	3.89	-0.23	3.87
EBIT Less CapEx to Interest Expense	2.61	2.49	2.13	1.86	0.54	2.80	2.92	4.81	-0.47	4.97
NOPAT Less CapEx to Interest Expense	1.62	1.57	1.33	6.14	0.35	2.05	2.30	3.74	-0.34	3.72
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-139.60%	39.87%	7.21%	0.00%	-60.75%	11.94%

This table displays calculated financial ratios and metrics derived from Prestige Consumer Healthcare's official financial filings.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.93%	4.72%	0.38%	7.09%	0.81%	-1.02%	2.62%	-3.11%	-4.36%	-0.88%	2.68%
EBITDA Growth	-4.41%	7.02%	3.41%	-411.98%	-0.46%	4.52%	0.25%	133.93%	-15.62%	-4.83%	3.88%
EBIT Growth	-5.75%	7.05%	4.39%	-464.64%	0.28%	5.32%	0.13%	129.44%	-17.22%	-4.63%	6.34%
NOPAT Growth	-1.80%	8.28%	5.00%	-397.36%	-2.63%	3.82%	-0.44%	130.68%	-8.38%	-4.66%	5.77%
Net Income Growth	-4.30%	12.57%	3.46%	-561.84%	-3.61%	4.97%	2.11%	120.56%	-7.90%	1.53%	15.05%
EPS Growth	-4.39%	14.61%	5.05%	-570.59%	-2.75%	4.90%	1.92%	120.42%	-7.55%	1.87%	15.09%
Operating Cash Flow Growth	-15.96%	-5.97%	-17.13%	-6.56%	-17.44%	8.55%	30.09%	13.43%	13.91%	11.75%	-8.93%
Free Cash Flow Firm Growth	94.27%	138.88%	138.65%	163.60%	315.73%	429.85%	525.76%	-31.68%	-80.23%	-79.51%	-84.85%
Invested Capital Growth	8.00%	-0.03%	0.28%	-9.52%	-9.00%	-9.22%	-9.69%	-0.14%	-0.24%	-0.26%	0.55%
Revenue Q/Q Growth	3.79%	4.41%	-4.75%	3.75%	-2.29%	2.51%	-1.25%	-2.03%	-3.56%	6.23%	2.30%
EBITDA Q/Q Growth	9.86%	-2.74%	2.36%	-385.25%	135.05%	2.13%	-1.82%	-3.45%	-12.85%	15.19%	7.16%
EBIT Q/Q Growth	12.02%	-3.04%	2.95%	-426.09%	130.81%	1.84%	-2.13%	-4.14%	-13.36%	17.32%	9.13%
NOPAT Q/Q Growth	2.55%	-4.69%	2.84%	-395.82%	133.58%	1.62%	-1.37%	-8.84%	0.28%	5.74%	9.42%
Net Income Q/Q Growth	6.12%	-7.69%	1.82%	-563.04%	122.15%	0.53%	-0.96%	-6.76%	-0.79%	10.82%	12.24%
EPS Q/Q Growth	6.86%	-6.42%	1.96%	-561.54%	122.08%	0.94%	-0.93%	-7.55%	0.00%	11.22%	11.93%
Operating Cash Flow Q/Q Growth	-7.73%	-1.21%	-4.52%	7.36%	-18.48%	29.89%	14.43%	-6.39%	-18.13%	27.43%	-6.75%
Free Cash Flow Firm Q/Q Growth	-6.73%	141.60%	-11.60%	62.06%	262.01%	2.17%	4.40%	-82.31%	4.74%	5.88%	-22.79%
Invested Capital Q/Q Growth	-0.39%	-0.19%	0.64%	-9.57%	0.19%	-0.44%	0.11%	0.00%	0.08%	-0.45%	0.92%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	57.79%	55.66%	54.59%	53.79%	55.38%	55.89%	55.86%	54.81%	54.66%	55.46%	55.47%
EBITDA Margin	34.43%	32.08%	34.47%	-94.77%	34.00%	33.87%	33.68%	33.19%	29.99%	32.53%	34.07%
Operating Margin	31.41%	29.17%	31.64%	-98.30%	30.50%	30.82%	30.71%	29.66%	26.97%	29.72%	31.68%
EBIT Margin	31.11%	28.89%	31.23%	-98.14%	30.94%	30.74%	30.47%	29.81%	26.78%	29.58%	31.55%
Profit (Net Income) Margin	19.95%	17.64%	18.86%	-84.15%	19.07%	18.71%	18.76%	17.86%	18.37%	19.16%	21.02%
Tax Burden Percent	77.96%	76.62%	76.27%	80.31%	77.53%	76.06%	76.24%	73.46%	84.00%	75.88%	76.14%
Interest Burden Percent	82.26%	79.68%	79.17%	106.76%	79.50%	80.00%	80.76%	81.52%	81.64%	85.37%	87.50%
Effective Tax Rate	22.04%	23.38%	23.73%	0.00%	22.47%	23.94%	23.76%	26.54%	16.00%	24.12%	23.86%
Return on Invested Capital (ROIC)	9.16%	8.16%	8.77%	-26.69%	9.20%	9.13%	9.14%	8.89%	9.13%	9.10%	9.75%
ROIC Less NNEP Spread (ROIC-NNEP)	8.27%	7.25%	7.77%	-29.84%	8.27%	8.10%	8.10%	7.98%	8.16%	8.24%	8.91%
Return on Net Nonoperating Assets (RNNOA)	7.87%	7.03%	7.02%	-27.51%	7.40%	6.76%	6.22%	6.22%	6.11%	5.64%	5.63%
Return on Equity (ROE)	17.03%	15.18%	15.79%	-54.21%	16.60%	15.89%	15.36%	15.11%	15.23%	14.74%	15.39%
Cash Return on Invested Capital (CROIC)	1.09%	8.66%	8.41%	9.45%	8.84%	9.17%	9.69%	9.55%	9.44%	9.38%	8.66%
Operating Return on Assets (OROA)	9.41%	8.70%	9.35%	-31.51%	9.95%	9.88%	9.75%	10.06%	8.96%	9.88%	10.58%
Return on Assets (ROA)	6.03%	5.31%	5.64%	-27.02%	6.13%	6.01%	6.00%	6.02%	6.15%	6.40%	7.05%
Return on Common Equity (ROCE)	17.03%	15.18%	15.79%	-54.21%	16.60%	15.89%	15.36%	15.11%	15.23%	14.74%	15.39%
Return on Equity Simple (ROE_SIMPLE)	12.80%	12.88%	12.47%	0.00%	-5.69%	-5.32%	-5.04%	0.00%	12.20%	11.89%	11.96%
Net Operating Profit after Tax (NOPAT)	68	65	66	-197	66	67	66	60	61	64	70
NOPAT Margin	24.48%	22.35%	24.13%	-68.81%	23.65%	23.44%	23.41%	21.79%	22.65%	22.55%	24.12%
Net Nonoperating Expense Percent (NNEP)	0.88%	0.91%	1.01%	3.14%	0.93%	1.03%	1.04%	0.90%	0.97%	0.86%	0.84%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	2.36%	-	-	-	2.49%
Cost of Revenue to Revenue	42.21%	44.34%	45.41%	46.21%	44.62%	44.11%	44.14%	45.19%	45.34%	44.54%	44.53%
SG&A Expenses to Revenue	9.64%	9.14%	9.63%	9.68%	9.91%	9.08%	9.20%	9.55%	10.82%	9.19%	9.02%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	26.39%	26.49%	22.94%	152.08%	24.88%	25.07%	25.15%	25.15%	27.69%	25.74%	23.80%
Earnings before Interest and Taxes (EBIT)	86	84	86	-281	86	88	86	83	72	84	92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	95	93	95	-271	95	97	95	92	80	92	99
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.87	1.53	1.84	2.15	2.00	1.84	1.90	2.18	2.04	2.06	2.16
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.70	2.24	2.80	2.76	2.61	2.51	2.68	3.20	3.09	3.22	3.45
Price to Earnings (P/E)	14.57	11.89	14.74	0.00	0.00	0.00	0.00	17.21	16.75	17.35	18.03
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	6.86%	8.41%	6.78%	0.00%	0.00%	0.00%	0.00%	5.81%	5.97%	5.76%	5.55%
Enterprise Value to Invested Capital (EV/IC)	1.45	1.28	1.46	1.60	1.53	1.47	1.52	1.70	1.63	1.66	1.74
Enterprise Value to Revenue (EV/Rev)	4.02	3.50	4.02	3.91	3.74	3.58	3.69	4.17	4.04	4.12	4.32
Enterprise Value to EBITDA (EV/EBITDA)	12.19	10.57	12.03	360.42	358.16	252.46	257.55	12.37	12.36	12.72	13.29
Enterprise Value to EBIT (EV/EBIT)	13.59	11.79	13.38	0.00	0.00	0.00	0.00	13.66	13.71	14.11	14.64
Enterprise Value to NOPAT (EV/NOPAT)	17.10	14.81	16.79	0.00	0.00	0.00	0.00	18.06	17.71	18.22	18.95
Enterprise Value to Operating Cash Flow (EV/OCF)	17.67	15.82	19.04	19.20	19.24	17.98	17.34	18.84	17.61	17.39	18.81
Enterprise Value to Free Cash Flow (EV/FCFF)	138.16	14.76	17.36	16.05	16.47	15.20	14.85	17.80	17.26	17.72	20.15
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.93	0.89	0.85	0.94	0.90	0.82	0.75	0.68	0.65	0.61	0.57
Long-Term Debt to Equity	0.93	0.89	0.85	0.94	0.90	0.82	0.75	0.68	0.65	0.61	0.57
Financial Leverage	0.95	0.97	0.90	0.92	0.89	0.83	0.77	0.78	0.75	0.68	0.63
Leverage Ratio	2.41	2.39	2.31	2.32	2.29	2.22	2.16	2.15	2.10	2.04	1.97
Compound Leverage Factor	1.98	1.90	1.83	2.48	1.82	1.78	1.74	1.75	1.72	1.74	1.72
Debt to Total Capital	48.23%	47.09%	46.02%	48.40%	47.25%	45.13%	42.96%	40.65%	39.52%	37.78%	36.32%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	48.23%	47.09%	46.02%	48.40%	47.25%	45.13%	42.96%	40.65%	39.52%	37.78%	36.32%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	51.77%	52.91%	53.98%	51.60%	52.75%	54.87%	57.04%	59.35%	60.48%	62.22%	63.68%
Debt to EBITDA	4.09	3.93	3.89	110.91	112.41	79.01	74.29	2.99	3.02	2.92	2.81
Net Debt to EBITDA	3.99	3.81	3.65	106.13	107.78	75.25	70.37	2.87	2.92	2.78	2.67
Long-Term Debt to EBITDA	4.09	3.93	3.89	110.91	112.41	79.01	74.29	2.99	3.02	2.92	2.81
Debt to NOPAT	5.74	5.50	5.42	-86.51	-78.16	-88.59	-83.12	4.36	4.32	4.19	4.00
Net Debt to NOPAT	5.60	5.34	5.10	-82.78	-74.94	-84.38	-78.74	4.19	4.19	3.98	3.81
Long-Term Debt to NOPAT	5.74	5.50	5.42	-86.51	-78.16	-88.59	-83.12	4.36	4.32	4.19	4.00
Altman Z-Score	1.76	1.66	1.87	1.59	1.96	1.98	2.11	2.38	2.36	2.48	2.66
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.09	2.21	2.55	2.44	2.66	2.99	3.09	3.20	3.23	3.56	3.68
Quick Ratio	1.17	1.24	1.52	1.40	1.44	1.68	1.87	1.91	1.80	2.01	2.13
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-157	65	58	94	340	347	362	64	67	71	55
Operating Cash Flow to CapEx	5,563.23%	2,421.72%	3,047.25%	2,305.98%	3,255.72%	2,128.83%	3,580.76%	2,128.76%	4,754.86%	3,443.51%	4,156.51%
Free Cash Flow to Firm to Interest Expense	-10.29	3.86	3.23	4.94	19.16	19.71	21.85	4.20	5.11	5.79	4.79
Operating Cash Flow to Interest Expense	3.81	3.39	3.07	3.11	2.71	3.55	4.31	4.38	4.17	5.68	5.68
Operating Cash Flow Less CapEx to Interest Expense	3.74	3.25	2.97	2.97	2.63	3.38	4.19	4.18	4.08	5.52	5.55
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.30	0.30	0.32	0.32	0.32	0.32	0.34	0.33	0.33	0.34
Accounts Receivable Turnover	7.94	7.57	7.61	7.36	7.45	7.40	6.85	6.55	6.75	6.90	6.55
Inventory Turnover	3.95	3.89	3.69	3.56	3.36	3.37	3.31	3.33	3.09	3.13	3.34
Fixed Asset Turnover	15.61	15.83	15.91	15.92	16.10	16.03	16.21	15.32	15.31	15.25	15.54
Accounts Payable Turnover	10.62	10.24	9.36	8.48	8.80	10.10	9.80	9.85	10.21	13.17	17.06
Days Sales Outstanding (DSO)	45.98	48.20	47.95	49.58	49.00	49.30	53.32	55.75	54.04	52.91	55.74
Days Inventory Outstanding (DIO)	92.35	93.93	98.95	102.60	108.62	108.38	110.38	109.61	118.11	116.47	109.13
Days Payable Outstanding (DPO)	34.37	35.63	39.00	43.04	41.49	36.12	37.23	37.06	35.74	27.72	21.39
Cash Conversion Cycle (CCC)	103.96	106.49	107.90	109.13	116.13	121.56	126.47	128.30	136.40	141.67	143.48
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,040	3,035	3,054	2,762	2,767	2,755	2,758	2,758	2,760	2,748	2,773
Invested Capital Turnover	0.37	0.37	0.36	0.39	0.39	0.39	0.39	0.41	0.40	0.40	0.40
Increase / (Decrease) in Invested Capital	225	-0.82	8.61	-290	-274	-280	-296	-3.73	-6.61	-7.08	15
Enterprise Value (EV)	4,397	3,879	4,452	4,411	4,225	4,036	4,180	4,690	4,501	4,573	4,827
Market Capitalization	2,956	2,480	3,100	3,112	2,953	2,833	3,038	3,603	3,437	3,573	3,858
Book Value per Share	$31.52	$32.55	$34.06	$29.12	$29.79	$31.00	$32.26	$33.34	$33.67	$34.94	$36.20
Tangible Book Value per Share	($33.31)	($32.69)	($31.50)	($28.63)	($27.84)	($26.63)	($25.31)	($24.03)	($23.35)	($22.48)	($21.24)
Total Capital	3,061	3,061	3,125	2,804	2,806	2,799	2,806	2,789	2,779	2,783	2,809
Total Debt	1,476	1,441	1,438	1,357	1,326	1,263	1,206	1,134	1,098	1,052	1,020
Total Long-Term Debt	1,476	1,441	1,438	1,357	1,326	1,263	1,206	1,134	1,098	1,052	1,020
Net Debt	1,440	1,399	1,352	1,299	1,271	1,203	1,142	1,087	1,064	1,000	969
Capital Expenditures (CapEx)	1.05	2.38	1.80	2.56	1.48	2.93	2.00	3.14	1.15	2.03	1.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)	133	142	162	173	190	198	203	212	220	222	224
Debt-free Net Working Capital (DFNWC)	169	184	249	231	244	258	266	258	255	274	275
Net Working Capital (NWC)	169	184	249	231	244	258	266	258	255	274	275
Net Nonoperating Expense (NNE)	13	14	15	44	13	14	13	11	11	9.62	8.99
Net Nonoperating Obligations (NNO)	1,456	1,415	1,367	1,315	1,286	1,219	1,157	1,103	1,079	1,016	985
Total Depreciation and Amortization (D&A)	9.21	9.22	8.95	9.61	8.53	8.96	9.07	9.36	8.58	8.36	7.30
Debt-free, Cash-free Net Working Capital to Revenue	12.19%	12.81%	14.64%	15.30%	16.81%	17.61%	17.87%	18.80%	19.80%	20.01%	20.01%
Debt-free Net Working Capital to Revenue	15.46%	16.64%	22.43%	20.49%	21.64%	22.94%	23.48%	22.93%	22.87%	24.65%	24.56%
Net Working Capital to Revenue	15.46%	16.64%	22.43%	20.49%	21.64%	22.94%	23.48%	22.93%	22.87%	24.65%	24.56%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.10	$1.02	$1.05	($4.82)	$1.07	$1.08	$1.07	$0.99	$0.98	$1.10	$1.23
Adjusted Weighted Average Basic Shares Outstanding	50.26M	49.80M	49.69M	49.89M	49.77M	49.69M	49.74M	49.76M	49.89M	49.65M	49.60M
Adjusted Diluted Earnings per Share	$1.09	$1.02	$1.04	($4.80)	$1.06	$1.07	$1.06	$0.98	$0.98	$1.09	$1.22
Adjusted Weighted Average Diluted Shares Outstanding	50.73M	50.27M	50.19M	49.89M	50.20M	50.08M	50.13M	50.18M	50.27M	50.00M	49.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.76M	49.53M	49.69M	49.69M	49.54M	49.62M	49.65M	49.92M	49.56M	49.41M	49.54M
Normalized Net Operating Profit after Tax (NOPAT)	68	65	66	-197	66	67	66	60	61	64	70
Normalized NOPAT Margin	24.48%	22.35%	24.13%	-68.81%	23.65%	23.44%	23.41%	21.79%	22.65%	22.55%	24.12%
Pre Tax Income Margin	25.59%	23.02%	24.72%	-104.78%	24.60%	24.59%	24.61%	24.30%	21.87%	25.25%	27.61%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	5.64	4.92	4.80	-14.78	4.88	5.00	5.20	5.41	5.45	6.84	8.00
NOPAT to Interest Expense	4.44	3.81	3.71	-10.37	3.73	3.81	3.99	3.96	4.61	5.21	6.11
EBIT Less CapEx to Interest Expense	5.57	4.78	4.70	-14.92	4.79	4.83	5.08	5.21	5.36	6.67	7.86
NOPAT Less CapEx to Interest Expense	4.37	3.67	3.61	-10.50	3.64	3.65	3.87	3.75	4.52	5.05	5.98
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	18.59%	23.97%	23.77%	-60.75%	-44.21%	-30.58%	-30.99%	11.94%	12.66%	18.35%	18.79%

Frequently Asked Questions About Prestige Consumer Healthcare's Financials

When does Prestige Consumer Healthcare's financial year end?

According to the most recent income statement we have on file, Prestige Consumer Healthcare's fiscal year ends in March. Their fiscal year 2024 ended on March 31, 2024.

How has Prestige Consumer Healthcare's net income changed over the last 9 years?

Over the last 9 years, Prestige Consumer Healthcare's net income changed from $78.26 million in 2015 to $209.34 million in 2024, a change of 167.5%.

What is Prestige Consumer Healthcare's operating income?

Prestige Consumer Healthcare's total operating income in 2024 was $342.43 million, based on the following breakdown:

Total Gross Profit: $624.45 million
Total Operating Expenses: $282.02 million

How has Prestige Consumer Healthcare revenue changed over the last 9 years?

Over the last 9 years, Prestige Consumer Healthcare's total revenue changed from $714.62 million in 2015 to $1.13 billion in 2024, a change of 57.5%.

How much debt does Prestige Consumer Healthcare have?

Prestige Consumer Healthcare's total liabilities were at $1.66 billion at the end of 2024, a 12.8% decrease from 2023, and a 17.4% decrease since 2015.

How much cash does Prestige Consumer Healthcare have?

In the past 9 years, Prestige Consumer Healthcare's cash and equivalents has ranged from $21.32 million in 2015 to $94.76 million in 2020, and is currently $46.47 million as of their latest financial filing in 2024.

How has Prestige Consumer Healthcare's book value per share changed over the last 9 years?

Over the last 9 years, Prestige Consumer Healthcare's book value per share changed from 12.01 in 2015 to 33.34 in 2024, a change of 177.6%.

Remove Ads

Related Companies

This page (NYSE:PBH) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prestige Consumer Healthcare (PBH) Financials

Frequently Asked Questions About Prestige Consumer Healthcare's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prestige Consumer Healthcare (PBH) Financials

Annual Income Statements for Prestige Consumer Healthcare

Quarterly Income Statements for Prestige Consumer Healthcare

Annual Cash Flow Statements for Prestige Consumer Healthcare

Quarterly Cash Flow Statements for Prestige Consumer Healthcare

Annual Balance Sheets for Prestige Consumer Healthcare

Quarterly Balance Sheets for Prestige Consumer Healthcare

Annual Metrics and Ratios for Prestige Consumer Healthcare

Quarterly Metrics and Ratios for Prestige Consumer Healthcare

Frequently Asked Questions About Prestige Consumer Healthcare's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools